Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Rapport Therapeutics CDO Yeleswaram Krishnaswamy sells $808,844 stock By Investing.com
Rapport Therapeutics’ Chief Development Officer, Yeleswaram Krishnaswamy, sold 20,225 shares of the company’s common stock for over $808,000 on April 17, 2026, through a pre-arranged trading plan. Despite the sale, the company’s stock has seen a significant annual increase, though it is currently considered overvalued according to InvestingPro. Meanwhile, Rapport Therapeutics recently announced positive Phase 2a trial results for its epilepsy drug RAP-219, leading to accelerated Phase 3 trials and reiterated “Buy” ratings from several analysts.